Zinc gluconate lozenges for treating the common cold. A randomized, double-blind, placebo-controlled study

Area of Science:

• Internal Medicine
• Pharmacology

Background:

• The common cold is a frequent illness causing significant morbidity and economic loss.
• No consistently effective therapy for the common cold is well-documented.
• Zinc presents potential mechanisms for effective common cold treatment.

Purpose of the Study:

• To evaluate the efficacy of zinc gluconate lozenges in alleviating common cold symptom duration.
• To compare the effectiveness of zinc gluconate against a placebo in a randomized controlled trial.

Main Methods:

• A randomized, double-blind, placebo-controlled study was conducted.
• 100 participants with common cold symptoms received either zinc gluconate lozenges or placebo lozenges.
• Daily symptom scores for various cold symptoms were recorded.

Main Results:

• Zinc gluconate significantly reduced the overall duration of common cold symptoms (median 4.4 vs. 7.6 days).
• Significant reductions were observed in days with cough, headache, hoarseness, nasal congestion, nasal drainage, and sore throat.
• Increased side effects, including nausea and bad taste, were reported in the zinc group.

Conclusions:

• Zinc gluconate lozenges effectively shorten the duration of common cold symptoms.
• The exact mechanism by which zinc acts on the common cold remains undetermined.
• Patients should consider the balance between potential benefits and adverse effects of zinc gluconate.